查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870945

按療法、疾病、最終用戶和給藥途徑分類的鬱血性心臟衰竭市場—2025-2032年全球預測

Congestive Heart Failure Market by Treatment Type, Disease Type, End User, Delivery Methods - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，鬱血性心臟衰竭市場將成長至 96.2 億美元，複合年成長率為 7.60%。

關鍵市場統計數據
基準年 2024 53.5億美元
預計年份：2025年 57.3億美元
預測年份 2032 96.2億美元
複合年成長率 (%) 7.60%

從策略層面建構鬱血性心臟衰竭的臨床、技術和政策促進因素框架，以塑造短期至中期內的治療路徑和相關人員的優先事項。

鬱血性心臟衰竭仍是臨床醫師、醫療系統和創新者面臨的核心挑戰，亟需整合臨床、技術和政策因應措施。藥理學、器材治療和外科技術的進步正與數位醫療和遠距監測相結合，從而改變不同醫療機構中患者的診斷、分層和管理方式。同時，支付方的期望和日益嚴格的監管要求相關人員在實際療效和成本效益的基礎上，證明其臨床獲益。本文闡述了臨床背景，重點介紹了核心技術和治療層級，並提出了領導者為實現更佳治療效果必須應對的策略挑戰框架。

本文對正在重塑心臟衰竭治療患者路徑和商業性需求的治療、數位化和報銷政策方面的融合變革進行了實用性綜述。

在治療方法、分析技術和醫療服務模式創新推動下，鬱血性的心臟衰竭格局正在改變。藥物研發的進步，例如調節神經激素通路藥物的擴展以及具有血糖控制以外作用的新興藥物類別，正在改變第一線治療和聯合治療策略。同時，器械治療也在從單一矯正裝置發展到能夠實現同步起搏、預防心律不整和生理監測的整合系統，從而支持更具適應性和個人化的治療管理。

對影響心臟衰竭藥物和醫療設備供應鏈的新關稅措施的營運、採購和患者獲取方面的影響進行戰略評估

2025年生效的新關稅可能會重塑與心臟衰竭治療及相關器械相關的供應鏈經濟格局、採購行為和戰略採購決策。對原料、電子元件和成品醫療設備徵收更高的關稅，可能會增加依賴全球組裝和零件採購的器材製造商的到岸成本。為應對這一變化，製造商可能會加快生產回流，擴大其區域製造地，或重新談判供應商契約，以緩解利潤壓縮並確保關鍵零部件的供應。

將治療方法、疾病亞型、臨床環境和給藥方式與臨床應用促進因素和商業化策略聯繫起來的詳細細分分析

對鬱血性心臟衰竭領域進行細分，有助於明確臨床需求、商業性機會和技術主導差異化之間的交集。治療方法涵蓋器械治療、藥物治療和外科手術，每種療法都有其獨特的決策因素和證據要求。在器械治療方面，心臟再同步化治療和植入式心臟整流去顫器等技術越來越重視封閉回路型感知、電池壽命以及與遠端監測平台的兼容性。藥物類別包括血管緊張素轉換酶抑制劑、醛固酮拮抗劑、血管收縮素II受體阻斷劑、 BETA阻斷劑、利尿劑以及一系列除血糖控制外還能帶來心血管獲益的新型藥物。對藥物耐受性、依從性和製劑創新的比較評估會影響處方模式和指南的更廣泛應用。冠狀動脈繞道手術手術、瓣膜修復術和心室輔助裝置等外科手術對於晚期患者仍然至關重要，隨著手術技術的改進和手術全期管理的最佳化，患者的生存率和康復情況也在不斷提高。

美洲、歐洲、中東和非洲以及亞太地區在技術採納和監管方面的差異，將決定臨床創新能否轉化為永續的商業性效益。

受不同管理體制、報銷模式和醫療基礎設施的影響，區域趨勢正在推動該地區加速投資、創新和應用。在美洲，活躍的臨床試驗、成熟的公私支付方體係以及較高的醫院採納率，共同為那些療效顯著且能節省成本的醫療設備和藥物創造了有利條件。北美醫療中心往往是醫療設備創新和大型多中心試驗的早期採用者，這些試驗會影響全部區域的指南更新和支付方決策。

企業策略和跨部門合作優先考慮整合醫療設備、藥品和數位化解決提案，以滿足臨床需求和支付方的價值標準。

鬱血性心臟衰竭領域的主要企業正在調整其研發、夥伴關係和商業策略，以平衡短期市場准入挑戰與長期差異化發展。現有製藥公司持續最佳化其以神經激素調節和輔助性治療為核心的產品組合策略，而生物製藥參與企業致力於探索獨特的藥物作用機制、提高耐受性以及與數位化藥物管理工具的整合。醫療設備製造商正投資於硬體的迭代改進和軟體服務，以增強遠端監測、電池效率和演算法心律不整檢測能力，從而建立整合式醫療生態系統，而非僅僅銷售獨立的硬體。

為加速推廣應用並維持臨床影響，提出切實可行的經營團隊建議，旨在將綜合證據產生、多元化供應鏈和基本契約連結起來。

產業領導者應採取果斷措施，使臨床創新與商業性可行性和系統層面的價值創造相契合。首先，應優先進行整合證據項目，將隨機數據與實際應用的真實世界證據相結合，從而同時滿足臨床醫生、支付方和監管機構的需求。以病人為中心的研究設計將縮短商業化週期，並有助於醫保報銷談判。其次，應投資模組化生產和區域供應多元化，以降低關稅和物流風險，同時加快大型醫院和醫療系統對採購週期的反應。

為了支持我們的策略洞察力，我們採用透明、多方面的調查方法，整合臨床證據審查、專家訪談、供應鏈分析和監管資訊分析。

本分析的調查方法結合了多源證據綜合、專家相關人員對話以及臨床和商業資料流的三角驗證。我們對同行評審的臨床文獻、監管申報文件和主要指南修訂進行了全面審查，以確定檢驗的作用機制和醫療設備效能指標。此外，我們也諮詢了執業心臟病專家、介入外科醫生、醫院採購人員和生命科學公司高管，以了解臨床實踐中的決策促進因素和應用障礙，從而進一步完善了臨床基礎。

一份簡明扼要的綜述強調，整合證據、供應鏈韌性和夥伴關係主導的商業化是實現心臟衰竭治療持續改善的途徑。

總之，鬱血性心臟衰竭領域正處於一個轉折點，治療方法創新、醫療設備的日益精進和數位化醫療模式與不斷變化的政策和採購趨勢交織在一起。產業和臨床相關人員的成功將取決於能否獲得可靠、多方面的證據，能否設計出互通性和以患者為中心的醫療技術，以及能否建立符合支付方對有效治療效果要求的商業性模式。供應鏈的韌性和區域製造策略可能會影響近期的醫療服務可近性，尤其是在關稅和貿易不確定性的情況下。同時，合作式的商業模式可以降低推廣門檻，加速規模化應用。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • SGLT2抑制劑在心臟衰竭中的廣泛應用可降低住院率並提高存活率
  • 用於預測風險分層和個人化心臟衰竭治療策略的新興人工智慧平台
  • 整合遠端患者監護設備，以收集即時血流動力學數據並協調干預措施
  • 擴大針對心肌重塑路徑基因治療的研究，以解決慢性心臟衰竭的根本原因。
  • 開發一種聯合使用腦啡肽酶抑制劑和血管緊張素受體阻斷劑的藥物治療方法，以改善心臟功能
  • 利用遠端醫療的跨專業照護模式對於降低心臟衰竭患者的再入院率變得越來越重要。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依治療類型分類的鬱血性心臟衰竭市場

  • 器械療法
    • 心臟再同步治療
    • 植入式心臟整流去顫器
  • 藥物治療
    • ACE抑制劑
    • 醛固酮拮抗劑
    • 血管收縮素II受體阻斷劑
    • BETA阻斷劑
    • 利尿劑
    • SGLT2抑制劑
  • 手術介入
    • 冠狀動脈繞道手術手術
    • 心臟瓣膜修復
    • 心室輔助裝置

第9章 依疾病類型分類的鬱血性心臟衰竭

  • 急性心臟衰竭
  • 慢性心臟衰竭
  • 左心臟衰竭
    • 舒張性心衰竭
    • 收縮性心臟衰竭
  • 右心臟衰竭

第10章 依最終用戶分類的鬱血性心臟衰竭市場

  • 醫院和診所
    • 私人診所
    • 公立醫院
  • 研究所

第11章鬱血性心臟衰竭市場（依管理方式）

  • 注射
  • 口服
  • 經皮

第12章鬱血性心臟衰竭市場：依地區分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章鬱血性心臟衰竭市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國鬱血性心臟衰竭市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Abbott Laboratories
    • Alnylam Pharmaceuticals, Inc.
    • Amgen Inc.
    • AstraZeneca
    • Bayer AG
    • Becton, Dickinson and Company
    • Biotronik SE & Co. KG
    • Boehringer Ingelheim International GmbH
    • Boston Scientific Corporation
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Medtronic plc
    • Merck & Co., Inc.
    • Novartis AG
    • Otsuka Pharmaceutical Co., Ltd.
    • Pfizer Inc.
    • ResMed Inc.
    • Sanofi Group
    • Servier Laboratories
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-1A1A064C04DC

The Congestive Heart Failure Market is projected to grow by USD 9.62 billion at a CAGR of 7.60% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.35 billion
Estimated Year [2025] USD 5.73 billion
Forecast Year [2032] USD 9.62 billion
CAGR (%) 7.60%

A strategic framing of the congestive heart failure clinical, technological, and policy drivers shaping care pathways and stakeholder priorities over the near to medium term

Congestive heart failure remains a central challenge for clinicians, health systems, and innovators, driving an urgent need for integrated clinical, technological, and policy responses. Advances in pharmacology, device therapy, and surgical techniques are converging with digital health and remote monitoring to change how patients are diagnosed, stratified, and managed across care settings. At the same time, payer expectations and regulatory scrutiny push stakeholders to demonstrate real-world effectiveness and cost-conscious clinical benefit. This introduction establishes the clinical context, highlights the pivotal technologies and therapeutic classes, and frames the strategic tensions that leaders must navigate to deliver improved outcomes.

Clinicians continue to emphasize earlier detection and more personalized treatment pathways, which has prompted greater attention to biomarkers, imaging innovations, and ambulatory monitoring. Industry players are responding with devices that integrate diagnostics and therapy, medications that target pathophysiologic mechanisms with improved tolerability, and procedural refinements that reduce perioperative risk. Policy and reimbursement environments are responding as well, encouraging outcome-based contracting and pathways that prioritize value over volume. Taken together, these forces require a coordinated response across suppliers, providers, and policy-makers to translate innovation into sustained improvements in morbidity and quality of life for patients living with heart failure.

An actionable review of converging therapeutic, digital, and reimbursement shifts that are redefining patient pathways and commercial imperatives in heart failure care

The landscape for congestive heart failure care is undergoing transformative shifts driven by innovations in therapy, analytics, and care delivery. Pharmacologic advances such as the expansion of agents that modulate neurohormonal pathways and emerging classes that show benefits beyond glycemic control are altering first-line and combination therapy strategies. Simultaneously, device therapy has evolved from discrete corrective devices to integrated systems that enable synchronized pacing, arrhythmia prevention, and physiologic sensing, which supports more adaptive and individualized management.

Digital health and remote monitoring catalyze earlier intervention and reduce avoidable hospital encounters by enabling continuous physiologic assessment and prompt clinical triage. These capabilities are reshaping care pathways from episodic to longitudinal models and shifting the locus of care toward ambulatory settings and virtual platforms. At the same time, health policy trends toward value-based contracting and outcome-linked reimbursement place sustained emphasis on demonstrating meaningful clinical benefit and lowering total cost of care. Together, these shifts create new commercial imperatives for clinical evidence generation, interoperability, patient engagement strategies, and supply chain resilience.

A strategic assessment of the operational, procurement, and patient access consequences driven by new tariff measures affecting heart failure therapeutics and device supply chains

The introduction of new tariff measures in 2025 has the potential to reconfigure supply chain economics, procurement behavior, and strategic sourcing decisions relevant to heart failure therapies and supporting devices. Tariff increases on raw materials, electronic components, and finished medical devices can raise landed costs for device manufacturers who rely on globalized assembly and component sourcing. In response, manufacturers may accelerate onshoring, expand regional manufacturing footprints, or renegotiate supplier contracts to mitigate margin compression and preserve access to critical components.

Health systems and hospital procurement teams can experience immediate budgetary pressure as device acquisition costs rise, which often triggers more stringent evaluation protocols, extended tender cycles, and an increased focus on total cost of ownership. Payers and integrated delivery networks could push for price concessions or demand stronger evidence of durability and real-world outcomes before approving capital purchases. At the same time, tariff-driven cost inflation may incentivize local suppliers and smaller manufacturers to capture niche opportunities, particularly for components and consumables where domestic capacity can scale quickly. Policymakers and industry leaders will need to collaborate on tariff exemptions for critical medical supplies, strategic stockpiling, and trade dialogues to avoid unintended disruptions to clinical care and to maintain continuity of treatment for vulnerable patients.

Granular segmentation insights that connect therapeutic modalities, disease subtypes, care settings, and delivery formats to clinical adoption drivers and commercialization strategies

Segmenting the congestive heart failure landscape clarifies where clinical need intersects with commercial opportunity and technology-driven differentiation. Treatment types span device therapy, medication, and surgical intervention, each with distinct decision drivers and evidence requirements. Within device therapy, technologies that deliver cardiac resynchronization and those that provide implantable cardioversion increasingly emphasize closed-loop sensing, battery longevity, and compatibility with remote interrogation platforms. Medication classes include ACE inhibitors, aldosterone antagonists, angiotensin II receptor blockers, beta blockers, diuretics, and the newer class of agents that confer cardiovascular benefit beyond glycemic control; comparative tolerability, adherence, and formulation innovation influence prescribing patterns and broader guideline uptake. Surgical interventions such as coronary artery bypass grafting, valve repair, and ventricular assist devices remain essential for advanced disease, and procedural refinement plus perioperative optimization continues to improve survival and recovery trajectories.

Disease-type stratification is equally consequential, with acute and chronic heart failure presenting different care pathways and resource intensities. Left-sided heart failure, encompassing both diastolic and systolic dysfunction, often requires nuanced pharmacologic and device strategies tailored to ejection fraction status, while right-sided heart failure presents unique hemodynamic and comorbidity challenges that influence therapeutic choices. End-user segmentation identifies hospitals and clinics alongside research institutes as primary adoption channels; within hospitals and clinics, private and public institutions navigate different procurement rules, budget cycles, and adoption thresholds that affect how new therapies and devices scale. Delivery methods-injectable, oral, and transdermal-introduce formulation and adherence considerations that shape patient acceptance and long-term regimen persistence. Integrating these segmentation lenses supports targeted clinical evidence generation, differentiated value propositions for payers, and market access approaches that align with care setting realities.

Regional adoption and regulatory contrasts across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine where clinical innovation translates into sustainable commercial traction

Regional dynamics shape where investment, innovation, and adoption accelerate, driven by differing regulatory regimes, reimbursement models, and care infrastructures. In the Americas, robust clinical trial activity, a mature private and public payer mix, and high hospital adoption rates create fertile ground for devices and pharmaceuticals that demonstrate definitive outcome improvements and cost offsets. North American centers often serve as early adopters for device-based innovation and large multicenter trials, which in turn inform guideline updates and payer decisions across the region.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization efforts coexist with diverse reimbursement environments. Western European markets typically emphasize health technology assessment and strong post-market surveillance, which favors innovations with clear comparative effectiveness data. Emerging markets within the broader region may prioritize cost-effective interventions and scalable delivery models, creating opportunities for lower-cost devices, simplified delivery methods, and task-shifting strategies that extend specialist care into community settings.

Asia-Pacific exhibits rapid growth in both clinical capacity and local manufacturing capabilities, coupled with increasing public investment in cardiovascular infrastructure. Many health systems in the region emphasize scalable solutions that address large patient volumes and workforce constraints, driving interest in remote monitoring, minimally invasive procedures, and oral therapeutic regimens that require fewer specialist touchpoints. Regulatory pathways in several Asia-Pacific markets have also shortened approval timelines for breakthrough technologies, encouraging quick market entry when companies can demonstrate robust clinical benefit and adaptability to local care models.

Company strategies and cross-sector collaborations that prioritize integrated device, pharmaceutical, and digital propositions to meet clinical demands and payer value criteria

Key companies operating across the congestive heart failure landscape are aligning R&D, partnerships, and commercial strategies to balance near-term access challenges with long-term differentiation. Established pharmaceutical firms continue to refine portfolio strategies around neurohormonal modulation and adjunctive therapies, while biopharma entrants pursue niche mechanisms and improved tolerability profiles that can be paired with digital adherence tools. Device manufacturers are investing in iterative hardware improvements and software-enabled services that enhance remote monitoring, battery efficiency, and algorithmic arrhythmia detection, thereby creating integrated care ecosystems rather than standalone hardware sales.

Collaborative models between device makers, pharmaceutical companies, and technology vendors are increasingly common, reflecting the need to bundle clinical evidence and service offerings that demonstrate measurable reductions in hospital admissions and improved patient-reported outcomes. Mergers, selective licensing agreements, and strategic alliances focus on accelerating regulatory submissions, expanding geographic reach, and combining complementary technologies, especially where cross-disciplinary integration delivers a clear clinical advantage. For many organizations, the strategic playbook prioritizes scalable solutions that meet payer expectations for value and providers' demand for ease of integration into existing workflows.

Actionable executive recommendations that connect integrated evidence generation, diversified supply chains, and value-based contracting to accelerate adoption and sustain clinical impact

Industry leaders should take decisive steps to align clinical innovation with commercial viability and system-level value creation. First, prioritize integrated evidence programs that combine randomized data with pragmatic real-world evidence to satisfy clinicians, payers, and regulators simultaneously; designing studies that capture patient-centered outcomes will shorten commercialization timelines and support reimbursement discussions. Second, invest in modular manufacturing and regional supply diversification to reduce tariff and logistics exposure while enabling faster response to procurement cycles in key hospitals and health systems.

Third, forge strategic partnerships that unite device interoperability, pharmacologic optimization, and digital engagement to offer bundled solutions which demonstrably reduce readmissions and improve functional status. Fourth, adopt flexible pricing and contracting frameworks, including outcome-linked agreements, to bridge adoption gaps in cost-sensitive settings and to share risk with payers. Fifth, accelerate deployment of remote monitoring and telehealth-enabled care pathways to shift care upstream and reduce acute episode frequency; this requires investment in clinician training and seamless integration with electronic health records. Finally, maintain a disciplined focus on health economics and value communication so that product teams can articulate total cost of care benefits to hospitals, integrated delivery networks, and national health authorities.

A transparent and multi-source research methodology integrating clinical evidence review, expert interviews, supply chain analysis, and regulatory intelligence to underpin strategic findings

The research methodology underpinning this analysis combined multi-source evidence synthesis, expert stakeholder engagement, and triangulation across clinical and commercial data streams. We performed an exhaustive review of peer-reviewed clinical literature, regulatory filings, and major guideline updates to identify validated therapeutic mechanisms and device performance metrics. This clinical foundation was enriched by consultations with practicing cardiologists, interventional surgeons, hospital procurement leaders, and life-science executives to capture decision-making drivers and adoption barriers across care settings.

Operational intelligence incorporated an assessment of manufacturing and supply chain structures, procurement practices, and policy developments relevant to tariffs and trade. Where possible, clinical trial registries and public safety databases provided orthogonal validation of device performance characteristics and adverse event profiles. All qualitative inputs were cross-checked against published clinical endpoints and regulatory milestones to ensure accuracy, and the resulting insights were stress-tested through scenario analysis to evaluate the implications of policy shifts, reimbursement changes, and technology adoption curves.

A concise synthesis emphasizing integrated evidence, supply resilience, and partnership-driven commercialization as the pathways to durable improvements in heart failure care

In conclusion, the congestive heart failure landscape is at an inflection point where therapeutic innovation, device sophistication, and digital care models intersect with evolving policy and procurement dynamics. Success for industry and clinical stakeholders depends on generating robust, multi-dimensional evidence; designing interoperable and patient-centric technologies; and structuring commercial approaches that align with payer demands for meaningful outcomes. Supply chain resilience and regional manufacturing strategies will influence near-term access, particularly in the face of tariff and trade uncertainty, while collaborative commercial models can lower adoption barriers and accelerate scale.

Moving forward, organizations that integrate clinical, operational, and commercial disciplines will capture the greatest value while improving patient outcomes. A disciplined focus on health economic evidence, targeted regional strategies, and partnerships that bundle technology with services will enable sustainable adoption. Ultimately, the path to better care for patients with congestive heart failure requires coordination across research, clinical practice, and health system leadership to translate innovation into accessible, durable improvement in clinical and quality-of-life metrics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing utilization of SGLT2 inhibitors in heart failure to reduce hospitalizations and improve survival rates
  • 5.2. Emerging artificial intelligence platforms for predictive risk stratification and personalized heart failure treatment strategies
  • 5.3. Integration of remote patient monitoring devices enabling real time hemodynamic data collection and intervention adjustments
  • 5.4. Expansion of gene therapy research targeting myocardial remodeling pathways to address underlying causes of chronic heart failure
  • 5.5. Development of combination pharmacotherapy approaches combining neprilysin inhibitors with ARBs for enhanced cardiac function
  • 5.6. Increasing emphasis on telehealth enabled multidisciplinary care models to reduce readmission rates in heart failure populations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Congestive Heart Failure Market, by Treatment Type

  • 8.1. Device Therapy
    • 8.1.1. Cardiac Resynchronization Therapy
    • 8.1.2. Implantable Cardioverter Defibrillators
  • 8.2. Medication
    • 8.2.1. ACE Inhibitors
    • 8.2.2. Aldosterone Antagonists
    • 8.2.3. Angiotensin II Receptor Blockers
    • 8.2.4. Beta Blockers
    • 8.2.5. Diuretics
    • 8.2.6. SGLT2 Inhibitors
  • 8.3. Surgical Intervention
    • 8.3.1. Coronary Artery Bypass Grafting
    • 8.3.2. Heart Valve Repair
    • 8.3.3. Ventricular Assist Devices

9. Congestive Heart Failure Market, by Disease Type

  • 9.1. Acute Heart Failure
  • 9.2. Chronic Heart Failure
  • 9.3. Left-Sided Heart Failure
    • 9.3.1. Diastolic Heart Failure
    • 9.3.2. Systolic Heart Failure
  • 9.4. Right-Sided Heart Failure

10. Congestive Heart Failure Market, by End User

  • 10.1. Hospitals and Clinics
    • 10.1.1. Private Clinics
    • 10.1.2. Public Hospitals
  • 10.2. Research Institutes

11. Congestive Heart Failure Market, by Delivery Methods

  • 11.1. Injectable
  • 11.2. Oral
  • 11.3. Transdermal

12. Congestive Heart Failure Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Congestive Heart Failure Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Congestive Heart Failure Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. Alnylam Pharmaceuticals, Inc.
    • 15.3.3. Amgen Inc.
    • 15.3.4. AstraZeneca
    • 15.3.5. Bayer AG
    • 15.3.6. Becton, Dickinson and Company
    • 15.3.7. Biotronik SE & Co. KG
    • 15.3.8. Boehringer Ingelheim International GmbH
    • 15.3.9. Boston Scientific Corporation
    • 15.3.10. Bristol-Myers Squibb Company
    • 15.3.11. Eli Lilly and Company
    • 15.3.12. F. Hoffmann-La Roche AG
    • 15.3.13. Gilead Sciences, Inc.
    • 15.3.14. GlaxoSmithKline plc
    • 15.3.15. Johnson & Johnson
    • 15.3.16. Medtronic plc
    • 15.3.17. Merck & Co., Inc.
    • 15.3.18. Novartis AG
    • 15.3.19. Otsuka Pharmaceutical Co., Ltd.
    • 15.3.20. Pfizer Inc.
    • 15.3.21. ResMed Inc.
    • 15.3.22. Sanofi Group
    • 15.3.23. Servier Laboratories
    • 15.3.24. Takeda Pharmaceutical Company Limited
    • 15.3.25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CONGESTIVE HEART FAILURE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CONGESTIVE HEART FAILURE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CONGESTIVE HEART FAILURE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BETA BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BETA BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BETA BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BETA BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIURETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIURETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIURETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIURETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIURETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIURETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HEART VALVE REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HEART VALVE REPAIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HEART VALVE REPAIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HEART VALVE REPAIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HEART VALVE REPAIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HEART VALVE REPAIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACUTE HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACUTE HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACUTE HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACUTE HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACUTE HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACUTE HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CHRONIC HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CHRONIC HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CHRONIC HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CHRONIC HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CHRONIC HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CHRONIC HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIASTOLIC HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIASTOLIC HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIASTOLIC HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIASTOLIC HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIASTOLIC HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIASTOLIC HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SYSTOLIC HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SYSTOLIC HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SYSTOLIC HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SYSTOLIC HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SYSTOLIC HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SYSTOLIC HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)